argenx SE Announces Advancement of ARGX-119 to Registrational Study for Congenital Myasthenic Syndromes Following Promising Phase 1b Results
I'm PortAI, I can summarize articles.
argenx SE has announced the advancement of ARGX-119 to a registrational study for congenital myasthenic syndromes (CMS) after positive Phase 1b results. The study showed a favorable safety profile and met its primary endpoint, with improvements noted in secondary endpoints such as the Six-Minute Walk Test and Myasthenia Gravis scores in treated DOK7-CMS patients. Detailed results will be presented at an upcoming medical meeting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments